AbbVie Inc.ABBV
AbbVie Inc. Financial Overview 2021–2025
Updated Jul 10, 2026Even as its former flagship drug Humira suffered a staggering 49.5% revenue collapse in FY2025, AbbVie expanded its total top line by 8.6% to reach $61.2 billion. The pharmaceutical giant has successfully bridged the industry's most anticipated patent cliff by aggressively pivoting its core immunology business toward two hyper-growth replacement assets.
This portfolio transition allowed total net revenue to grow from $56.2 billion in FY2021 to $61.2 billion in FY2025, definitively absorbing the biosimilar shock. By the end of this period, next-generation treatments Skyrizi and Rinvoq collectively accounted for roughly 42% of total revenues, posting massive year-over-year increases of 49.9% and 39.1% in FY2025. The company fueled this commercial shift with $19.0 billion in operating cash flow during the year, deploying capital toward strategic acquisitions like ImmunoGen and Cerevel Therapeutics to rebuild its oncology and neuroscience pipelines.
These aggressive pipeline investments and acquisition-related milestone expenses heavily compressed bottom-line profitability, dropping reported earnings to just $2.36 per share. Investors largely looked past this margin compression in favor of the successful revenue replacement. At the close of FY2025, the market valued the stock at $228.49, trading at a steep 96.8x earnings multiple as the company proved its new assets could carry the weight of the broader portfolio.
Recent Developments (Q4 2025 and Q1 2026)
In Q1 2026, AbbVie sustained its momentum with net revenues increasing 12.4% year-over-year to $15.0 billion. The immunology division remained the primary growth engine, with Skyrizi and Rinvoq revenues climbing 30.9% and 23.3%, respectively. The company optimized its capital structure by issuing $8.0 billion in senior notes in March 2026 to refinance a $2.0 billion term loan. AbbVie also absorbed a $744 million acquired IPR&D expense tied to an upfront license agreement payment with RemeGen.
Bulls highlight the diversified portfolio generating $3.8 billion in first-quarter operating cash flow. Conversely, bears note that aggressive pipeline investments pushed R&D expenses up 20% year-over-year to $2.5 billion, slashing quarterly earnings from $0.72 to just $0.39 per share. The stock remains richly valued at 85.4x earnings as of May 8, 2026, reflecting a continued market premium for its ongoing portfolio transition.
What to watch: clinical progress for RemeGen licensed assets; integration and pipeline impact of the upcoming Apogee Therapeutics acquisition.
Rev
$61.16B
FY2025
NI
$4.23B
FY2025
EPS
$2.37
FY2025
OCF
$19.03B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
AbbVie Inc. 8-K Report, Financial Results (Jul 6, 2026)
AbbVie Inc. (ABBV) has filed an 8-K detailing preliminary second-quarter 2026 financial expectations, specifically addressing the impact of acquired In-Process Research and Development (IPR&D) and milestones expense. The company anticipates a pre-tax charge of $291 million related to these expenses, which is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.17 each. While these are preliminary estimates and subject to final financial closing procedures, investors should note this significant expense impacting near-term profitability. Despite the unfavorable impact from acquired IPR&D and milestones, AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance, now projected to be between $13.91 and $14.11. This revised guidance range incorporates the estimated second-quarter expense. The company also provided a specific second-quarter 2026 adjusted diluted earnings per share guidance range of $3.57 to $3.61, which also includes this expense. Investors are reminded that acquired IPR&D and milestones are inherently unpredictable and are not typically forecasted beyond the initial quarter they are incurred.
AbbVie Inc. 8-K Report, Regulation FD Disclosure (Jun 22, 2026)
AbbVie Inc. (ABBV) announced a significant strategic move via a joint press release with Apogee Therapeutics, Inc. on June 22, 2026, detailing a definitive agreement for AbbVie to acquire Apogee. This acquisition signals AbbVie's commitment to expanding its pipeline and therapeutic offerings. While specific financial terms of the deal are not disclosed in this 8-K, the accompanying investor presentation (Exhibit 99.2) likely elaborates on the strategic rationale and potential financial impact. Investors should note that this filing is primarily for Regulation FD disclosure, providing public access to the press release and presentation materials. The report highlights forward-looking statements concerning the benefits of the acquisition, integration plans, and the potential of Apogee's pipeline assets, including zumilokibart (APG777). However, the company also outlines numerous risks and uncertainties associated with the transaction, common in M&A activities, which could materially affect future results.
AbbVie Inc. 8-K Report, Shareholder Vote Results (May 12, 2026)
AbbVie Inc. (ABBV) filed an 8-K on May 12, 2026, detailing the outcomes of its 2026 Annual Meeting of Stockholders held on May 8, 2026. The primary focus of the report is the voting results on several key corporate governance and business matters. Notably, all incumbent Class II directors were re-elected, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 was overwhelmingly ratified. Additionally, stockholders provided advisory approval for the compensation of the company's named executive officers. However, the meeting also saw the rejection of two significant management and stockholder proposals. The proposed amendment to the certificate of incorporation to eliminate supermajority voting requirements did not pass, indicating continued support for existing supermajority provisions among a portion of the shareholder base. Furthermore, a stockholder proposal advocating for a policy to require an independent board chair was also defeated, suggesting that the current board structure without an independent chair is favored by a majority of shareholders or that such a policy was not deemed necessary by a sufficient number of voters.
AbbVie Inc. 8-K Report, Financial Results (Apr 29, 2026)
AbbVie Inc. (ABBV) has filed an 8-K on April 29, 2026, to report its financial results for the first quarter ended March 31, 2026. The key information is contained within the furnished press release (Exhibit 99.1), which provides the company's performance metrics for the period. Investors should review this press release for details on revenue, earnings, and any forward-looking guidance issued by the company. While the 8-K itself is brief, it serves as the official vehicle to disseminate crucial financial updates. The furnished press release is the primary source for understanding AbbVie's operational and financial standing at the close of the first quarter of 2026. This includes any changes in strategic direction, significant product performance, or macroeconomic factors that may have influenced the results.
AbbVie Inc. 8-K Report, Financial Results (Apr 3, 2026)
AbbVie Inc. (ABBV) has filed a Form 8-K to provide preliminary information regarding its first quarter 2026 financial results, specifically detailing the impact of acquired In-Process Research & Development (IPR&D) and milestones expenses. The company anticipates these expenses will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.41. This expense, totaling $744 million pre-tax, was not previously included in the company's initial 2026 adjusted diluted EPS guidance, which was based on February 4, 2026, expectations. Despite this one-time charge, AbbVie has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 to $14.16, incorporating the first quarter's impact. The updated first quarter 2026 adjusted diluted EPS guidance range is now projected at $2.56 to $2.60. Investors should note that these are preliminary estimates and the final results are subject to financial statement closing procedures. The filing also includes standard forward-looking statement disclaimers highlighting potential risks and uncertainties.
View all 8-K filings →